Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab

OBJECTIVE: In patients with postoperative recurrence of Crohn’s disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg). However, in theory low-dose infliximab treated patients could develop subtherapeutic trough levels, infiximab antibodies,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorrentino, Dario, Marino, Marco, Dassopoulos, Themistocles, Zarifi, Dimitra, Del Bianco, Tiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680060/
https://www.ncbi.nlm.nih.gov/pubmed/26670274
http://dx.doi.org/10.1371/journal.pone.0144900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680060/
https://www.ncbi.nlm.nih.gov/pubmed/26670274
http://dx.doi.org/10.1371/journal.pone.0144900

Ejemplares similares